161 related articles for article (PubMed ID: 27426058)
21. PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer.
Woo S; Kim SY; Lee J; Kim SH; Cho JY
Eur Radiol; 2016 Oct; 26(10):3580-7. PubMed ID: 26847042
[TBL] [Abstract][Full Text] [Related]
22. Extreme Gleason Upgrading From Biopsy to Radical Prostatectomy: A Population-based Analysis.
Winters BR; Wright JL; Holt SK; Lin DW; Ellis WJ; Dalkin BL; Schade GR
Urology; 2016 Oct; 96():148-155. PubMed ID: 27313123
[TBL] [Abstract][Full Text] [Related]
23. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
24. Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.
Tilki D; Schlenker B; John M; Buchner A; Stanislaus P; Gratzke C; Karl A; Tan GY; Ergün S; Tewari AK; Stief CG; Seitz M; Reich O
Urol Oncol; 2011; 29(5):508-14. PubMed ID: 19837614
[TBL] [Abstract][Full Text] [Related]
25. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
[TBL] [Abstract][Full Text] [Related]
26. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer.
Truong M; Slezak JA; Lin CP; Iremashvili V; Sado M; Razmaria AA; Leverson G; Soloway MS; Eggener SE; Abel EJ; Downs TM; Jarrard DF
Cancer; 2013 Nov; 119(22):3992-4002. PubMed ID: 24006289
[TBL] [Abstract][Full Text] [Related]
27. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
28. Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer.
Hegde JV; Chen MH; Mulkern RV; Fennessy FM; D'Amico AV; Tempany CM
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):e101-7. PubMed ID: 23040223
[TBL] [Abstract][Full Text] [Related]
29. Use of the Prostate Health Index for the Detection of Aggressive Prostate Cancer at Radical Prostatectomy.
Mearini L; Nunzi E; Ferri C; Bellezza G; Lolli C; Porrozzi C; Porena M
Urol Int; 2015; 95(4):390-9. PubMed ID: 25792149
[TBL] [Abstract][Full Text] [Related]
30. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
31. Persistent Discordance in Grade, Stage, and NCCN Risk Stratification in Men Undergoing Targeted Biopsy and Radical Prostatectomy.
Alshak MN; Patel N; Gross MD; Margolis D; Hu JC
Urology; 2020 Jan; 135():117-123. PubMed ID: 31568795
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen levels of ≤4 and >4 ng/mL and risk of prostate cancer-specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer.
Kim DW; Chen MH; Wu J; Huland H; Graefen M; Tilki D; D'Amico AV
Cancer; 2021 Jul; 127(13):2222-2228. PubMed ID: 34101827
[TBL] [Abstract][Full Text] [Related]
33. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy.
D'Amico AV; Renshaw AA; Arsenault L; Schultz D; Richie JP
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):841-6. PubMed ID: 10571187
[TBL] [Abstract][Full Text] [Related]
34. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
35. Investigating association of perineural invasion on prostate biopsy with Gleason score upgrading at prostatectomy: A multi-institutional analysis.
Barsky AR; Kraus RD; Carmona R; Santos PMG; Li C; Schwartz LE; Ballas LK; Vapiwala N
Cancer Med; 2020 May; 9(10):3383-3389. PubMed ID: 32187859
[TBL] [Abstract][Full Text] [Related]
36. Role of multiparametric magnetic resonance imaging to predict postoperative Gleason score upgrading in prostate cancer with Gleason score 3 + 4.
Kim H; Kim JK; Hong SK; Jeong CW; Ku JH; Kwak C
World J Urol; 2021 Jun; 39(6):1825-1830. PubMed ID: 32869150
[TBL] [Abstract][Full Text] [Related]
37. Detecting recurrent prostate Cancer using multiparametric MRI, influence of PSA and Gleason grade.
Venkatesan AM; Mudairu-Dawodu E; Duran C; Stafford RJ; Yan Y; Wei W; Kundra V
Cancer Imaging; 2021 Jan; 21(1):3. PubMed ID: 33407861
[TBL] [Abstract][Full Text] [Related]
38. Predictors of unfavorable disease after radical prostatectomy in patients at low risk by D'Amico criteria: role of multiparametric magnetic resonance imaging.
Song SH; Pak S; Park S; Song C; Jeong IG; Choi HJ; Kim JK; Cho KS; Kim CS; Ahn H
J Urol; 2014 Aug; 192(2):402-8. PubMed ID: 24631106
[TBL] [Abstract][Full Text] [Related]
39. The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained: results from the Shared Equal Access Regional Cancer Hospital Database.
Turley RS; Terris MK; Kane CJ; Aronson WJ; Presti JC; Amling CL; Freedland SJ;
BJU Int; 2008 Nov; 102(9):1074-9. PubMed ID: 18778348
[TBL] [Abstract][Full Text] [Related]
40. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
